2026-10-29T22:39:16Zhttps://bayburt-rdlopen.rawdatalibrary.net/oai/request

oai:bayburt-rdlopen.rawdatalibrary.net:bayburt/113442026-10-29T19:41:35Zopenairecom_bayburt_10000col_bayburt_10001com_bayburt_10010col_bayburt_10222

Synthesis and cytotoxic activity studies of novel heterocyclic thiosemicarbazone compounds as anticancer agentsGüllü, EdaHasanoğlu Özkan, ElvanKızıl, Hamit EmreNartop, Dilekantiproliferative activityCVDK-8heteroaromaticlung cancer celltherapeutic agentthiosemicarbazoneHerein, novel heterocyclic thiosemicarbazone compounds (Hb1, Hb2, Hb3) containing pyrimidine, imidazole, pyridine, and phenyl rings were synthesized via the condensation method as potential therapeutic agents for the treatment of non-small cell lung cancer. The structure of novel heterocyclic compounds was elucidated by using some spectroscopic techniques (organic elemental analysis, fourier transform infrared spectroscopy, proton/carbon nuclear magnetic resonance spectroscopy, scanning electron microscopy and energy dispersive X-ray image, and molar conductance measurement). The antiproliferative activity of novel heterocyclic thiosemicarbazone compounds using CVDK-8 cell viability assay. The viability assay was examined against A549 human non-small cell lung cancer cell line. All heterocyclic thiosemicarbazone compounds exhibited varying degrees of dose-dependent cytotoxic activity against A549 NSCLC cells. The results showed that the pyridine-based heterocyclic compound (Hb3) was the most potent antiproliferative agent, demonstrating a dose-dependent reduction in cell viability at concentrations of 50 µg/mL and higher.SAGE Publications Ltd2026Articlehttps://rdlopen.rawdatalibrary.net/r/bayburt/11344https://doi.org/10.1177/102412212614839961024-1221enMain Group Chemistryinfo:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/articlehttps://bayburt-rdlopen.rawdatalibrary.net/tr/items/bayburt/11344